| Symbol | ACUT |
|---|---|
| Name | ACCUSTEM SCIENCES INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 10001 United States NY 5 Penn Plaza 19th Floor |
| Telephone | 00 44 2074952379 |
| Fax | — |
| — | |
| Website | http://www.accustem.com |
| Incorporation | US |
| Incorporated On | 2020 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC;NASDAQ |
| Auditor | Mercurius & Associates LLP; |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001850767 |
| Description | Accustem is an early-stage life sciences company committed to developing and commercializing novel products for the treatment and management of all cancers. Our mission at AccuStem is to optimize outcomes for all patients with cancer across the globe. We take a holistic view of our role in oncology- we are here to empower patients and their care team with critical answers and tools, driving innovation in healthcare. By integrating different technologies and platforms under one umbrella, we believe we can be a stronger partner for patients, physicians, care teams and industry. Additional info from OTC: |
AccuStem Sciences Announces StemPrintER Pilot Study with National Surgical Adjuvant Breast and Bowel Project (NSABP)
Read moreAccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th
Read more(52% Neutral) ACCUSTEM SCIENCES, INC. (ACUT) Reports Net Loss for 2025-06-30
Read moreDirector CERRONE GABRIELE M 🟢 acquired 2.4K shares of Accustem Sciences Inc. (ACUT) at $1.10 Transaction Date: Jun 13, 2025 | Filing ID: 015197
Read moreDirector CERRONE GABRIELE M 🟢 acquired 37.2K shares of Accustem Sciences Inc. (ACUT) at $0.83 Transaction Date: Jun 11, 2025 | Filing ID: 015003
Read more(28% Negative) ACCUSTEM SCIENCES, INC. (ACUT) Reports Net Loss for 2025-03-31
Read moreNew Form NT 10-Q - Accustem Sciences Inc. Filed: 2025-05-15 AccNo: 0001641172-25-011029 Size: 29 KB
Read more